Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin ≥8%, ≥64 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan-O randomized trial.
Melanie Jane DaviesJulio RosenstockAmar AliDavid L Russell-JonesElisabeth SouhamiKaren PalmerChen JiElisabeth NiemoellerNeil SkolnikPublished in: Diabetes, obesity & metabolism (2021)
Adults with T2D and HbA1c ≥64 mmol/mol (≥8%) despite two OADs at screening achieved better glycaemic control with iGlarLixi versus iGlar or Lixi, without increased risk of hypoglycaemia versus iGlar.
Keyphrases